Ultrasound-stimulated CRISPR-CuNPs provide a potent, non-radiotoxic platform for targeted gene therapy. By integrating experimentally validated ultrasound parameters with KRAS gene silencing and curcumin-driven epigenetic activation of TP53 and PTEN, this approach achieves synergistic suppression of metastatic pulmonary cancer phenotypes. While sequencing-based genome-editing confirmation and long-term genomic stability studies remain necessary, this system holds significant promise for gene-enhancing, minimally invasive therapeutic strategies for the unborn.
Xu et al. (Wed,) studied this question.